Who is sponsoring NCT02109146?

NCT02109146 is sponsored by Zhejiang University.

What drugs are being tested in NCT02109146?

Interventions in NCT02109146: Prophylactic Transcatheter Arterial Chemoembolization, Observation.

What condition does NCT02109146 study?

NCT02109146 studies Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization.

Is NCT02109146 still recruiting?

NCT02109146 is currently completed. Last updated 29 May 2024.

Last reviewed 2024-05-29 · How we verify

NCT02109146

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Postoperative TACE(Transhepatic Arterial Chemotherapy And Embolization) for Patients With Hepatocellular Carcinoma

Completed Phase 3 Last updated 29 May 2024

What this trial tests

Phase 3 trial testing Prophylactic Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma in 332 participants. Completed in 13 May 2023.

Timeline

26 March 2014

Primary endpoint
13 May 2023

13 May 2023

Quick facts

Lead sponsor	Zhejiang University
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	332
Start date	26 March 2014
Primary completion	13 May 2023
Estimated completion	13 May 2023
Sites	1 location across China

Drugs / interventions tested

Prophylactic Transcatheter Arterial Chemoembolization — full drug profile →
Observation

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →
Transcatheter Arterial Chemoembolization — all drugs for Transcatheter Arterial Chemoembolization →

Sponsor

Zhejiang University

Who can join

Adults 18 to 80, any sex, with Hepatocellular Carcinoma or Transcatheter Arterial Chemoembolization. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

1. Hepatocellular carcinoma (HCC) is the most common primary malignancy of liver, representing the third leading cause of cancer-related death worldwide. 2. Its overall dismal prognosis is a result of high incidence rates of metastasis and postoperative recurrence, in particular the intrahepatic recurrence. 3. TACE is the most widely used primary treatment for unresectable HCC. It was also used as the optional treatment for relapsed disease. However, the efficacy of TACE used as adjuvant therapy following hepatectomy remains controversial.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Advancing Adjuvant Immunotherapy in Hepatocellular Carcinoma: A Comprehensive Review.
Akabane M, Chatzipanagiotou OP, Imaoka Y, Schenk A, et al · · 2025 · cited 1× · PMID 40589998 · DOI 10.2147/itt.s528709
Global Advances in Hepatocellular Carcinoma Research and Therapy in 2025
Hu B, Gao Q. · · 2026

Verify or expand the search:

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Other Zhejiang University trials

Trials by the same sponsor.

NCT07487402 — Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurr · EARLY_PHASE1 · not yet recruiting
NCT07480044 — A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly · NA · not yet recruiting
NCT07467005 — Video Double-Lumen Tube for Secondary Pulmonary Resection · NA · not yet recruiting
NCT07429461 — Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia · EARLY_PHASE1 · recruiting
NCT07240766 — HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02109146 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhejiang University
Last refreshed: 29 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02109146.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing